ARGATROBAN IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.
| Metabolism | Primarily hepatic metabolism via hydroxylation and aromatization of the tetrahydrothiophene moiety; minimal cytochrome P450 involvement. Approximately 25% of the dose is excreted unchanged in urine. |
| Excretion | Primarily hepatic (biliary) excretion: approximately 65% eliminated via bile into feces; renal excretion accounts for about 22% as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged to 181–269 minutes in patients with hepatic impairment. Clinical context: Short half-life allows rapid reversal of anticoagulation upon discontinuation. |
| Protein binding | Approximately 54% bound to human serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2–0.3 L/kg; predominantly confined to extracellular fluid, indicating limited tissue distribution. |
| Bioavailability | Intravenous only: 100% bioavailability by IV route. Not absorbed orally. |
| Onset of Action | Intravenous bolus: immediate anticoagulant effect (within minutes) as measured by prolongation of aPTT. Continuous infusion: therapeutic effect achieved within 1–3 hours. |
| Duration of Action | aPTT returns to baseline within 2–4 hours after discontinuation of infusion in patients with normal hepatic function; prolonged in hepatic impairment. |
| Molecular Weight | 526.66 |
Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain aPTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment, including end-stage renal disease (ESRD) on hemodialysis. |
| Liver impairment | For moderate hepatic impairment (Child-Pugh B): initial infusion rate 0.5 mcg/kg/min; adjust aPTT accordingly. For severe hepatic impairment (Child-Pugh C): initial infusion rate 0.25-0.5 mcg/kg/min; use lower end of range. Titrate carefully. |
| Pediatric use | Not approved for pediatric use; limited data available. In clinical studies for HIT, initial infusion rate 0.5-2 mcg/kg/min adjusted to aPTT. |
| Geriatric use | No specific dose adjustment required; consider increased sensitivity and monitor aPTT closely. |
| 1st trimester | Argatroban is a direct thrombin inhibitor with limited data in pregnancy. Animal studies have not shown teratogenicity, but there is a risk of hemorrhage. Use only if clearly needed. |
| 2nd trimester | Same as t1. Potential for hemorrhage in mother and fetus. Limited human data. |
| 3rd trimester | Increased risk of hemorrhage during delivery. May cause fetal bleeding. Use with caution if anticoagulation is necessary. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Likely minimal due to high molecular weight and protein binding (54%). Animal studies show limited placental transfer. |
| Breastfeeding | Unknown if distributed in human milk. Due to high molecular weight and protein binding, excretion is likely minimal. Use with caution; monitor infant for bleeding. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies at up to 5 times human AUC showed no fetal harm. No adequate human studies; risk cannot be excluded. Use only if clearly needed. First trimester: theoretical risk due to anticoagulation. Second/Third trimesters: increased risk of bleeding, placental abruption, preterm labor. |
| Fetal Monitoring | Monitor aPTT (target 1.5-3x baseline) at least daily, more frequently if unstable. Monitor CBC for hemorrhage signs. Fetal surveillance: nonstress test or biophysical profile if indicated for gestational age, especially if bleeding occurs. |
| Fertility Effects | No known effect on fertility; no reproductive toxicity in animal studies. Use in pregnant patients may impact uterine blood flow; theoretical risk of implantation failure due to anticoagulation. |
■ FDA Black Box Warning
Risk of bleeding including intracranial hemorrhage. Do not use in patients with active major bleeding or conditions with high risk of bleeding.
| Common Effects | fluid replacement |
| Serious Effects |
Active major bleedingHypersensitivity to argatrobanSevere hypotensionUncontrollable hemorrhage
| Precautions | Bleeding risk: Increased risk of major bleeding, especially in patients with renal impairment, hepatic impairment, or those receiving antiplatelet agents or thrombolytics., Hepatic impairment: Use with caution in patients with hepatic disease as metabolism may be affected., Renal impairment: Dose adjustment recommended for patients with moderate to severe renal impairment (CrCl <30 mL/min)., Hypersensitivity reactions: Reported, including anaphylaxis., Concomitant use with anticoagulants, antiplatelets, or thrombolytics increases bleeding risk. |
| Food/Dietary | No specific food interactions known. However, avoid excessive alcohol consumption as it may increase bleeding risk. |
| Clinical Pearls | Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia (HIT). Monitor aPTT closely, target 1.5-3 times baseline. No reversal agent available; half-life ~40-50 min. Dose adjustment needed for hepatic impairment. Do not mix with other drugs in IV line. Use with caution in patients with bleeding risk. |
| Patient Advice | Argatroban prevents blood clots; you will have regular blood tests to monitor its effect. · Report any unusual bleeding, bruising, or dark stools immediately. · Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor. · Tell all healthcare providers you are on argatroban before any procedure or surgery. · Do not stop or skip doses without consulting your doctor. |
Loading safety data…